Taysha Gene Therapies(TSHA) - 2025 Q4 - Annual Results

Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutof ; longer-term safety and ef icacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026 Reached written alignment with FDA on proposed PPQ and comparability strategy for commercial TSHA-102 manufacturing to support planned BLA submission package Conference call and webcast today at 8:30 AM ET Exhibit 99.1 Taysha Gene Therapies Reports Full-Year ...